GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mendus AB (CHIX:IMMUs) » Definitions » Institutional Ownership

Mendus AB (CHIX:IMMUS) Institutional Ownership : 1.43% (As of May. 28, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Mendus AB Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Mendus AB's institutional ownership is 1.43%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Mendus AB's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Mendus AB's Float Percentage Of Total Shares Outstanding is 0.00%.


Mendus AB Institutional Ownership Historical Data

The historical data trend for Mendus AB's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mendus AB Institutional Ownership Chart

Mendus AB Historical Data

The historical data trend for Mendus AB can be seen below:

2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30
Institutional Ownership 1.53 4.22 1.88 1.91 1.92 1.72 1.74 1.72 1.67 1.43

Mendus AB Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Mendus AB (CHIX:IMMUS) Business Description

Traded in Other Exchanges
Address
Vastra Tradgardsgatan 15, Stockholm, SWE, 11153
Mendus AB is a clinical-level biopharmaceutical company that focuses on the development of immunotherapies that address tumor recurrence and difficult-to-treat established tumors. Its operations consist of research and development for pharmaceuticals.

Mendus AB (CHIX:IMMUS) Headlines

No Headlines